AQIA (Aquiva Group) Common Stock: $0.07 Mil (As of Sep. 2008)


What is Aquiva Group Common Stock?

Aquiva Group AQIA Common Stock is $0.07 Mil as of Sep. 2008.

Aquiva Group's quarterly common stock increased from Mar. 2008 ($0.06 Mil) to Jun. 2008 ($0.07 Mil) and increased from Jun. 2008 ($0.07 Mil) to Sep. 2008 ($0.07 Mil).

Aquiva Group's annual common stock stayed the same from Mar. 2006 ($0.01 Mil) to Mar. 2007 ($0.01 Mil) but then increased from Mar. 2007 ($0.01 Mil) to Mar. 2008 ($0.06 Mil).

Aquiva Group Common Stock Historical Data

* Premium members only.

The historical data trend for Aquiva Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquiva Group Common Stock Chart

Aquiva Group Annual Data
Trend Mar06 Mar07 Mar08
Common Stock
0.01 0.01 0.06

Aquiva Group Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.07 0.07

Aquiva Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.07 Mil mean?
Aquiva Group (AQIA) has a Common Stock of $0.07 Mil as of Sep. 2008. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Aquiva Group and its competitors.
Is Aquiva Group's Common Stock too high?
Aquiva Group's current Common Stock is $0.07 Mil.
How does Aquiva Group's Common Stock compare to LOGQ and MUSS?
Aquiva Group's Common Stock of $0.07 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Software company?
A good Common Stock depends on the Software industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Aquiva Group and its competitors. Aquiva Group's current Common Stock is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquiva Group stock overvalued right now?
Aquiva Group (AQIA) has a current Common Stock of $0.07 Mil. The current Common Stock is $0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Aquiva Group (AQIA), the current Common Stock is $0.07 Mil as of Sep. 2008. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aquiva Group Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
Aquiva Group Inc is focused on commercializing materials science technologies in both existing and emerging markets. It has licensed a novel HiPNATM (Hydrogel with InterPenetrating Network Anchor) technology, branded as AquiFormTM, which is a versatile material with key properties, making it an attractive platform for various applications. These applications include transdermal patches that release active ingredients for skin care, nutraceuticals, and other healthcare and cosmetics markets. The company operates across three segments: Consumer Health, Wellness, & Cosmetics; Medical Device; and Therapeutics & Transdermal Drug-Delivery Systems (TDS). Additionally, it is building on an established partnership network and capabilities in contract development to expand its services to new areas.